Abstract Announcements

Abstract Announcements and Exceptions 

Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to the Annual Meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy.  These formal Exceptions require approval by ASCO prior to the information being made public.

The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2014 ASCO Annual Meeting:

Abstract #613
"Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy."

Abstract #638
"Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients."

 Abstract #6005
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).

Abstract #8000
"Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial."

Abstract #LBA8006^
"REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy."

Abstract #9008a
"Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma."

Abstract #9011^
“COMBI-d:  A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma.”